Lilly To Target Forteo For Severe Osteoporosis; Evista For Mild
Executive Summary
Lilly will position Forteo for use in more advanced osteoporosis patients upon approval, while Evista will continue to be used for earlier stages of the disease.
You may also be interested in...
Lilly Forteo "Approvable": Indications, Manufacturing Issues To Be Resolved
FDA and Lilly are continuing to discuss the appropriate patient populations for the osteoporosis agent Forteo, Lilly CEO Sidney Taurel told analysts Oct. 3.
Lilly Forteo Follow-Up Rat Osteosarcoma Study To Finish By End Of 2002
Lilly's follow-up Forteo (teriparatide) osteosarcoma study is expected to be completed by the end of 2002, FDA told the Endocrinologic and Metabolic Drugs Advisory Committee July 27.
Lilly Forteo Osteoporosis Indication Approval Recommended With Restrictions
Lilly's Forteo should be approved for treatment of osteoporosis in postmenopausal women but restricted either to high-risk patients or second-line use, FDA's Endocrinologic and Metabolic Drugs Advisory Committee recommended July 27.